NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.
In this NBC Louisiana feature, Dotmatics’ VP of Science & Technology, Phil Mounteney, shared how artificial intelligence is transforming the future of drug discovery. While it typically takes up to ten years to bring a new drug to market, AI has the potential to cut that timeline in half—making the process faster, more affordable, and even revealing new applications for existing compounds.
“Think of drug discovery as finding needles in massive haystacks of data,” said Mounteney. “AI acts like a magnet, helping researchers surface insights far more efficiently than traditional methods.”
The interview also addresses public questions around data privacy and security in AI-driven healthcare. Dotmatics’ AI systems keep sensitive data securely in-house—never shared with public chatbots.
AI in life sciences is an exciting and sometimes controversial topic. Watch the full video to hear how Dotmatics is helping shape this important evolution in healthcare.
Related
Scripps News America Tonight
Phil Mounteney, VP of Science and Technology at Dotmatics, explains in Scripps News America Tonight how Dotmatics Luma uses AI to transform scientific research and pharmaceutical drug discovery by accelerating innovation, lowering costs, and shortening time-to-market for modern laboratories.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.